News

Roche announces EC has approved Columvi to treat large B-cell lymphoma
Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...
pharmaphorum3d
AbbVie/Roche seek first-line CLL use for Venclexta combo
AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting. Roche has ...
pharmaphorum4d
Roche's MS drug Ocrevus priced in line with Novartis rival in UK
Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...
Zacks Investment Research on MSN4d
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
Roche RHHBY announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line ...
Pharmaceutical Technology on MSN4d
Roche’s Columvi combo gains EC approval for DLBCL
Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx ...
Reuters5d
Roche Holding AG
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain ...